Natural Capsules Limited announced the resignation of Mr. Pramod Kasat from his position as Independent Director at Natural Biogenex Private Limited, a material unlisted subsidiary of the company. The departure becomes effective immediately on August 17, 2026.

The company cited professional commitments as the reason for Mr. Kasat's decision to step down from the board. This disclosure was made pursuant to Regulation 30(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Resignation Details

Mr. Kasat tendered his resignation to the Board of Directors of Natural Biogenex Private Limited. In his resignation letter, he thanked the board and management for the opportunity to serve and wished the company continued success.

The company's compliance officer, Akshay Dutta, confirmed that the requisite details and a copy of the resignation letter have been enclosed with the exchange filings. Natural Capsules Limited has requested the stock exchanges to take this intimation on record.

Natural Capsules Limited has released the final voting results and scrutinizer’s report for its 33rd Annual General Meeting (AGM), which was conducted through video conferencing on August 12, 2026. The meeting, chaired by Independent Director Tekkar Yashwanth Prabhu, saw the approval of all six resolutions proposed by the board.

The company provided remote e-voting facilities from August 8 to August 11, 2026, with an additional window during the virtual meeting. Deepak Sadhu of Deepak Sadhu & Co served as the scrutinizer for the process. The record date for the meeting was August 5, 2026, with a total of 9,061 shareholders on record.

Voting Results Overview

All resolutions were passed with significant support from the promoter group, which holds 5,301,248 shares. Public non-institutional shareholders participated with 14,895 votes polled across various resolutions. No public institutional shares voted.

Key Governance Approvals

The ordinary business included the adoption of audited consolidated and standalone financial statements for the fiscal year ended March 31, 2026. This resolution received near-unanimous support, with only 184 votes cast against it out of over 5.3 million votes polled.

Shareholders also approved the following governance matters:

• Reappointment of Mrs. Jyoti Mundra as a director retiring by rotation.
• Reappointment of Mr. Laxminarayan Moondra as a director retiring by rotation.
• Reappointment of Mr. Laxminarayan Moondra as Whole Time Director for a three-year term with revised remuneration (Special Resolution).
• Approval of related party transactions with subsidiary Natural Biogenex Private Limited.
• Revision in remuneration for Mr. Shrey Mundra, General Manager – Marketing.

Promoter vs Public Participation

The promoter group demonstrated high engagement, voting in favor of all resolutions. For the financial statement adoption, promoters cast 5,298,987 votes in favor with zero against. Public non-institutional shareholders showed slightly more dissent, casting between 184 and 284 votes against specific resolutions, though their overall support remained above 98%.

No invalid votes were recorded for any resolution. The total number of members participating in e-voting ranged from 35 to 41 across different resolutions, reflecting varying levels of engagement among the 9,061 registered shareholders.